Prostanoid Receptors

Items 1-50 of 469

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. Prostaglandin E1 (PGE1) is the theoretical cyclooxygenase metabolite of dihomo-γ-linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans or other animals. The IC50 of PGE1 for the inhibition of ADP-induced human platelet aggregation is 40 nM.
  2. Prostaglandin F2α is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
  3. KW-8232 free base is an anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
  4. EP2 Receptor antagonist

    PF-04418948 is a potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM. Phase 1.
  5. prostaglandin F2α (PGF2α) analogue

    (+)-Cloprostenol is a prostaglandin F2α (PGF2α) analogue, and shows selective agonistic activity at the prostaglandin receptor.
  6. Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.
  7. MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH2, and other prostaglandins.
  8. CRTH2 receptor antagonist

    AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.
  9. prostaglandin (PG) antagonist

    Aligeron is a non-selective prostaglandin (PG) antagonist, and has vasodilatory properties.
  10. DP1 inhibitor

    Laropiprant is used in combination with niacin to reduce blood cholesterol. Laropiprant acts as a DP1 antagonist, reducing the vasodilation.
  11. EP4 receptor antagonist

    MK-2894 is a highly potent and selective second generation EP4 antagonist.
  12. EP4 antagonist

    MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist.
  13. EP4 antagonist

    ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
  14. Thromboxane A2 synthesis inhibitor

    Ozagrel is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.
  15. Prostaglandin D2 receptor CRTH2 antagonist

    CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist.
  16. Prostaglandin Receptor Agonist

    Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
  17. CRTH2 antagonist

    OC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist.
  18. prostanoid DP-receptor (DP1) agonist

    BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.
  19. prostaglandin F2α analog

    Cloprostenol is a synthetic analog of prostaglandin F2α (PGF2α). It is 200 times and 100 times more potent than PGF2α in terminating pregnancy in hamsters and rats, respectively, without the side effects associated with PGF2α.
  20. dual antagonist of TP/DP2

    BAY-u 3405 is an approved human medication for the treatment of allergic rhinitis that has documented activity as an antagonist of the thromboxane receptor (TP receptor).
  21. prostacyclin receptor agonist

    NS-304 is a selective prostacyclin IP1 receptor agonist (Ki values are 260 and 2100 nM and for human and rat IP receptors, and >10 μM for EP1-4, DP, FP, and TP receptors).
  22. CRTH2 antagonist

    ACT-129968 is a potent and selective CRTH2 antagonist.
  23. EP2 Agonist

    C-544326 is a potent and selective prostaglandin E2 receptor agonist with EC50 value of 2.8 nM.
  24. prostaglandin EP4 receptor antagonist

    Grapiprant is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
  25. Prostaglandin E2 receptor antagonist

    TG6-10-1 is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2.
  26. DP1 receptor antagonist

    Asapiprant, also known as S-555739, is a the potent and selective DP1 receptor antagonist. Asapiprant exhibited high affinity and selectivity for the DP1 receptor.
  27. EP2 receptor agonist

    Taprenepag isopropyl is a highly selective EP2 receptor agonist.
  28. thromboxane A2 synthase inhibitor

    Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC50s of about 10 nM.
  29. EP2 receptor antagonist

    TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM.
  30. prostaglandin D2 antagonist

    AMG-009 is a potent antagonist of prostaglandin D2, with IC50 of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.
  31. Prostanoid EP2 receptor agonist

    Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.
  32. thromboxane-prostaglandin receptor antagonist

    Terutroban is a thromboxane-prostaglandin receptor antagonist.
  33. CRTH2 antagonist

    MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5??0.5 nM.
  34. DP1/EP2 agonist

    Treprostinil sodium is a potent DP1 and EP2 agonist with EC50 values of 0.6??0.1 and 6.2??1.2 nM, respectively.
  35. IP receptor agonist

    Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
  36. PGE2 agonist

    Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.
  37. prostaglandin EP2 agonist

    AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.
  38. DP1 antagonist

    L 888607 Racemate is a selective prostaglandin D2 receptor subtype 1 (DP1) antagonist, with Kis of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.
  39. PGF2α receptor antagonist

    OBE022 is an oral and selective prostaglandin F2α (PGF2α) receptor antagonist, with Kis of 1 nM, 26 nM for human and rat FP receptors, respectively.
  40. EP4 antagonist

    E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.
  41. CRTh2 antagonist

    CRTh2 antagonist 1 is a CRTh2 antagonist with an IC50 of 89 nM.
  42. PGF2α analogue

    Tiaprost is a prostaglandin F2α (PGF2α) analogue.
  43. TXA2 receptor

    LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities.
  44. EP1 antagonist

    EP1-antanoist-1 is a EP1 antagonist with a pKi of 7.54 and an pIC50 of 8.5.
  45. Lipid-lowering Agent

    AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.
  46. CRTh2 receptor antagonist

    MK-8318 is a potent and selective CRTh2 receptor antagonist with a Ki of 5.0 nM.
  47. EP4 partial agonist

    GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC50 of 7.4.
  48. DP antagonist

    PGD2-IN-1 is an antagonist of DP extracted from patent WO 2006044732 A2, example 15 (d); has an IC50 of 0.3 nM.
  49. CRTH2/DP2 receptor antagonist

    CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM.
  50. CRTH2 antagonist

    BI-671800 is a CRTH2 antagonist that treats patients with asthma.

Items 1-50 of 469

Page
per page
Set Descending Direction